Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 746 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast... June 26, 2020 Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected May 16, 2019 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... March 27, 2025 Load more HOT NEWS ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People Speaking with One Cancer Voice for cancer patients in England FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T... EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib
